| 2025-11-06 |
复牌提示：
2025-11-06 09:40:17 停牌，复牌日期 2025-11-06 09:45:17
|
| 2025-09-30 |
详情>>
业绩披露：
2025年中报每股收益-0.19新加坡元,归母净利润-224.38万新加坡元,同比去年增长-106.15%
|
| 2025-08-18 |
详情>>
股本变动：
变动后总股本1173.37万股
|
| 2025-05-16 |
股东大会：
将于2025-06-26召开股东大会
会议内容 ▼▲
- 1.By an ordinary resolution, to receive and adopt the Directors’ Statement, the audited financial statements of the Company for the financial year ended December 31, 2024;
2.By an ordinary resolution, to receive and adopt the audited financial statements in relation to Form 20-F for the financial year ended December 31, 2024;
3.By an ordinary resolution, to approve the re-election of Dr. ZENG Jieming, who is retiring by rotation pursuant to Regulation 117 of the Constitution of the Company and who, being eligible, offers himself for re-election as Director;
4.By an ordinary resolution, to approve the re-election of Mr. Mark LEONG Kei Wei who is retiring by rotation pursuant to Regulation 117 of the Constitution of the Company and who, being eligible, offers himself for re-election as Director;
5.By an ordinary resolution, to approve the re-election of Prof. LOH Yuin Han who is retiring by rotation pursuant to Regulation 117 of the Constitution of the Company and who, being eligible, offers himself for re-election as Director;
6.By an ordinary resolution, to ratify the appointment of WWC, P.C., as the Company’s independent registered public accounting firm for the financial year ending December 31, 2025 and that the Directors be empowered to fix the auditors’ remuneration in their absolute discretion;
7.By an ordinary resolution, to ratify the appointment of KE Trust PAC as the Company’s independent registered public accounting firm for the financial year ending December 31, 2025 and that the Directors be empowered to fix the auditors’ remuneration in their absolute discretion;
8.By an ordinary resolution, to approve payment of Directors’ fees of US$70,000 for the financial year ending December 31, 2025.
9.By an ordinary resolution, to adjourn the Annual General Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Proposal One, Proposal Two, Proposal Three, Proposal Four, Proposal Five, Proposal Six, Proposal Seven, Proposal Eight, Proposal Ten, and Proposal Eleven.
10.By an ordinary resolution, to resolve that:
(a)Pursuant to Section 161 of the Singapore Companies Act 1967 (the “Singapore Companies Act”) the Directors be and are hereby authorized to issue such number of new ordinary shares in the capital of the Company as may be approved by the board of Directors (the “Board”), such shares to rank pari passu in all respects with the existing issued ordinary shares in the capital of the Company in connection with the initial public offering of the Company at the price(s) to be determined by the Board and on such terms and conditions as the Board may at any time and from time to time think fit and allot the same to such members of the public and/or private places who shall have applied for the shares in connection with the admission of the Company to Nasdaq, as the Board may decide.
(b)Pursuant to Section 161 of the Companies Act 1967 and all applicable laws (including but not limited to the listing rules of Nasdaq (the “Nasdaq Listing Rules”)), the Directors be and are hereby authorized to: (a) (i) issue (in addition to the new ordinary shares referred to in paragraph (a) above) new ordinary shares whether by way of rights, bonus or otherwise; and/or (ii) make or grant offers, agreements or options (collectively “Instruments”) that might or would require new ordinary shares to be issued during the continuance of this authority or thereafter, including but not limited to the creation and issue of (as well as adjustments to) options, warrants, debentures or other instruments convertible into new ordinary shares, at any time and upon such terms and conditions and for such purposes and to such persons as the Directors may in their absolute discretion deem fit; and (b) (notwithstanding this authorization conferred may have ceased to be in force) issue new ordinary shares in pursuance of any Instruments made or granted by the Directors while this authorization was in force, provided that:
(1)the aggregate number of new ordinary shares to be issued pursuant to such authority (including new ordinary shares to be issued in pursuance of the Instruments, made or granted pursuant to this authorization but excluding new ordinary shares which may be issued pursuant to any adjustments (“Adjustments”) effected under any relevant Instrument, which Adjustments shall be made in compliance with all applicable laws (including the Nasdaq Listing Rules) for the time being in force (unless such compliance has been waived by the Nasdaq) and the Constitution for the time being of the Company;
(2)in exercising such authority, the Company shall comply with all applicable laws, including the provisions of the Act, the Nasdaq Listing Rules for the time being in force (unless such compliance has been waived by the Nasdaq) and the Constitution for the time being of the Company;
(3)unless revoked or varied by the Company in a general meeting by ordinary resolution, such authority shall continue in force until (i) the conclusion of the next annual general meeting of the Company or (ii) the date by which the next annual general meeting of the Company is required by law to be held, whichever is earlier.
11.By a special resolution, alter Regulation 63(1) of the Constitution to remove the requirement to publish notice of general meetings in the daily press.
|
| 2025-04-28 |
详情>>
业绩披露：
2024年年报每股收益-0.22新加坡元,归母净利润-251.67万新加坡元,同比去年增长39.11%
|
| 2024-09-30 |
详情>>
业绩披露：
2024年中报每股收益-0.09新加坡元,归母净利润-108.84万新加坡元,同比去年增长49.57%
|
| 2024-09-30 |
详情>>
业绩披露：
2023年中报每股收益-0.22新加坡元,归母净利润-215.81万新加坡元,同比去年增长-116.83%
|
| 2024-04-24 |
股东大会：
将于2024-05-15召开股东大会
会议内容 ▼▲
- 1.By an ordinary resolution, to receive and adopt the Directors’ Statement, the audited financial statements of the Company for the financial year ended December 31, 2023.
2.By an ordinary resolution, to receive and adopt the audited financial statements in relation to Form 20-F for the financial year ended December 31, 2023December 31, 2023.
3.By an ordinary resolution, to approve the re-election of Mr. Choo Chee Keong who is retiring by rotation pursuant to Regulation 117 of the Constitution of the Company and who, being eligible, offers himself for re-election as a Director, to serve a term expiring at the next annual general meeting of shareholders or until his successor is duly elected and qualified. To also note the resignation of Mr. Wu Tao Thomas and Dr Lucas Luk Tien Wee as Directors. Both have given notice to the Company that they do not wish to stand for re-election as Directors.
4.By an ordinary resolution, to ratify the appointment of WWC, P.C., as the Company’s independent registered public accounting firm for the financial year ending December 31, 2024 and that the Directors be empowered to fix the auditors’ remuneration in their absolute discretion.
5.By an ordinary resolution, to ratify the appointment of KE Trust PAC as the Company’s independent registered public accounting firm for the financial year ending December 31, 2024 and that the Directors be empowered to fix the auditors’ remuneration in their absolute discretion.
6.By an ordinary resolution, to approve payment of Directors’ fees of US$90,000 for the financial year ending December 31, 2024, and payment of Directors’ fees of US$70,000 for the financial year ended December 31, 2023.
7.By an ordinary resolution, to adjourn the Annual General Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Proposal One, Proposal Two, Proposal Three, Proposal Four or Proposal Five.
8.By an ordinary resolution, to resolved that:(c)Pursuant to Section 161 of the Singapore Companies Act 1967 (the “Singapore Companies Act”) the Directors be and are hereby authorised to issue such number of new ordinary shares in the capital of the Company as may be approved by the board of Directors (the “Board”), such shares to rank pari passu in all respects with the existing issued ordinary shares in the capital of the Company in connection with the initial public offering of the Company at the price(s) to be determined by the Board and on such terms and conditions as the Board may at any time and from time to time think fit and allot the same to such members of the public and/or private placees who shall have applied for the shares in connection with the admission of the Company to Nasdaq, as the Board may decide.(d)Pursuant to Section 161 of the Companies Act 1967 and all applicable laws (including but not limited to the listing rules of Nasdaq (the “Nasdaq Listing Rules”)), the Directors be and are hereby authorized to: (a) (i) issue (in addition to the new ordinary shares referred to in paragraph (a) above) new ordinary shares whether by way of rights, bonus or otherwise; and/or (ii) make or grant offers, agreements or options (collectively “Instruments”) that might or would require new ordinary shares to be issued during the continuance of this authority or thereafter, including but not limited to the creation and issue of (as well as adjustments to) options, warrants, debentures or other instruments convertible into new ordinary shares, at any time and upon such terms and conditions and for such purposes and to such persons as the Directors may in their absolute discretion deem fit; and (b) (notwithstanding this authorization conferred may have ceased to be in force) issue new ordinary shares in pursuance of any Instruments made or granted by the Directors while this authorization was in force, provided that:(4)the aggregate number of new ordinary shares to be issued pursuant to such authority (including new ordinary shares to be issued in pursuance of the Instruments, made or granted pursuant to this authorization but excluding new ordinary shares which may be issued pursuant to any adjustments (“Adjustments”) effected under any relevant Instrument, which Adjustments shall be made in compliance with all applicable laws (including the Nasdaq Listing Rules) for the time being in force (unless such compliance has been waived by the Nasdaq) and the Constitution for the time being of the Company;(5)in exercising such authority, the Company shall comply with all applicable laws, including the provisions of the Act, the Nasdaq Listing Rules for the time being in force (unless such compliance has been waived by the Nasdaq) and the Constitution for the time being of the Company;unless revoked or varied by the Company in a general meeting by ordinary resolution, such authority shall continue in force until (i) the conclusion of the next annual general meeting of the Company or (ii) the date by which the next annual general meeting of the Company is required by law to be held, whichever is earlier.
|
| 2024-04-22 |
详情>>
业绩披露：
2023年年报每股收益-0.39新加坡元,归母净利润-413.29万新加坡元,同比去年增长-31.99%
|
| 2023-05-01 |
详情>>
业绩披露：
2022年年报每股收益-0.4新加坡元,归母净利润-313.12万新加坡元,同比去年增长-52.62%
|
| 2023-02-21 |
详情>>
业绩披露：
2021年中报每股收益-0.16新加坡元,归母净利润-102.53万新加坡元,同比去年增长-93.74%
|
| 2023-02-21 |
详情>>
业绩披露：
2020年年报每股收益-0.33新加坡元,归母净利润-193.54万新加坡元,同比去年增长-127.5%
|
| 2023-02-21 |
详情>>
业绩披露：
2021年年报每股收益-0.3新加坡元,归母净利润-205.16万新加坡元,同比去年增长-6%
|
| 2023-02-21 |
详情>>
业绩披露：
2022年中报每股收益-0.13新加坡元,归母净利润-99.53万新加坡元,同比去年增长2.92%
|
| 2021-03-15 |
热点提醒：
美股今天进入夏令时交易，盘前交易开始时间提前至北京时间16：00
|